Victor Stefanescu on Muck Rack

Victor Stefanescu

Verified
Minneapolis
As seen in: The Minnesota Star Tribune, MSN, The Wall Street Journal, Yahoo Finance, Boston.com, Chicago Tribune, Chron, Flipboard, The Boston Globe, The Seattle Times, Miami Herald and
covering the business of food @startribune - victor.stefanescu@startribune.com - signal vic_stef.79

Get in touch with Victor

Contact Victor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history

|
By Giri Viswanathan, Victor Stefanescu Verified
| The Brunswick News Verified
By Giri Viswanathan and Victor Stefanescu, The Minnesota Star Tribune Germany's Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, which makes lab materials and equipment used to develop drugs.
Open in Who Shared View Duplicates (2) Issue with article?

Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history

|
By Giri Viswanathan, Victor Stefanescu Verified
| Fort Worth Star-Telegram Verified
Germany's Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, which makes lab materials and equipment used to develop drugs. Bio-Techne's stock had fallen nearly 50% in five years while Merck KGaA - one of Germany's largest pharmaceutical companies that is unrelated to New Jersey-based Merck & Co. - was looking to grow through acquisitions under a new CEO.
Open in Who Shared View Duplicates (31) Issue with article?

Merck buying Twin Cities medtech firm Bio-Techne for $11.3B

|
By Victor Stefanescu Verified, Catherine Roberts Verified
| The Minnesota Star Tribune Verified
Production technicians manufacture hematology controls at Bio-Techne. The company is being sold to Merck. (Anthony Soufflé/The Minnesota Star Tribune) Comment Gift Share Merck will buy Minneapolis-based Bio-Techne Corp. in a deal worth $11.3 billion. For Merck, based in Darmstadt, Germany, it is an early move by new CEO Kai Beckmann. “This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda,” Beckmann said in a statement.
Open in Who Shared Issue with article?
See all 1,630 licensed articles (1,871 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified